secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001193125-23-297614
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum's LIVMARLI fails Phase 2b EMBARK trial in biliary atresia; primary endpoint not met
--------------------------------------------------------------------------------

- Phase 2b EMBARK trial of LIVMARLI (maralixibat) in biliary atresia did not meet primary or key secondary endpoints.
- LIVMARLI was generally well-tolerated with no new safety findings.
- Topline results announced on December 18, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523297614/0001193125-23-297614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523297614/d784519d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-297614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer